<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PHL</journal-id>
<journal-id journal-id-type="hwp">spphl</journal-id>
<journal-title>Phlebology</journal-title>
<issn pub-type="ppub">0268-3555</issn>
<issn pub-type="epub">1758-1125</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1258/phleb.2012.012051</article-id>
<article-id pub-id-type="publisher-id">10.1258_phleb.2012.012051</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Willenberg</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff1-phleb.2012.012051">*</xref>
<xref ref-type="aff" rid="aff2-phleb.2012.012051">†</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Smith</surname><given-names>P C</given-names></name>
<xref ref-type="aff" rid="aff3-phleb.2012.012051">‡</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shepherd</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-phleb.2012.012051">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Davies</surname><given-names>A H</given-names></name>
<xref ref-type="aff" rid="aff1-phleb.2012.012051">*</xref>
<xref ref-type="corresp" rid="corresp1-phleb.2012.012051"/>
</contrib>
</contrib-group>
<aff id="aff1-phleb.2012.012051"><label>*</label>Academic Section of Vascular Surgery Imperial College School of Medicine Charing Cross Hospital, London, UK</aff>
<aff id="aff2-phleb.2012.012051"><label>†</label>University Hospital Berne, Swiss Cardiovascular Centre, Division of Clinical and Interventional Angiology, Switzerland</aff>
<aff id="aff3-phleb.2012.012051"><label>‡</label>British Vein Institute, 4 Upper Wimpole Street, London, UK</aff>
<author-notes>
<corresp id="corresp1-phleb.2012.012051"><bold>A H Davies</bold>, Professor of Vascular Sugery, 4 East Department of Vascular Surgery, Fulham Palace Road W6 8RF, UK. Email: <email>a.h.davies@imperial.ac.uk</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>3</issue>
<fpage>123</fpage>
<lpage>131</lpage>
<history>
<date date-type="accepted">
<day>27</day>
<month>7</month>
<year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The objective of the study was to review the literature reporting visual disturbance (VD) following sclerotherapy for varicose veins. Underlying mechanisms will be discussed. A literature search of the databases Medline and Google Scholar was performed. Original articles including randomized trials, case series and case reports reporting VD in humans following sclerotherapy for varicose veins were included. Additional references were also obtained if they had been referenced in related publications. The search yielded 4948 results of which 25 reports were found to meet the inclusion criteria. In larger series with at least 500 included patients the prevalence of VD following sclerotherapy ranges from 0.09% to 2%. In most reports foam sclerotherapy was associated with VD (19); exclusive use of liquid sclerosant was reported in two cases, some reports included foam and liquid sclerosant (4). There were no persistent visual disorders reported. VD occurred with polidocanol and sodium tetradecyl sulphate in different concentrations (0.25–3%). Various forms of foam preparation including various ways of foam production and the liquid – air ratio (1 or 2 parts of liquid mixed with 3, 4 or 5 parts of air) were reported in association with the occurrence of VD. VDs following sclerotherapy for varicose veins are rare and all reported events were transient. Bubble embolism or any kind of embolism seems unlikely to be the only underlying mechanism. A systemic inflammatory response following sclerotherapy has been suggested. Further research to clarify the mechanism of action of sclerosants is required.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>sclerotherapy</kwd>
<kwd>varicose veins</kwd>
<kwd>visual disturbance</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-phleb.2012.012051" sec-type="intro"><title>Introduction</title>
<p>Varicose veins pose a substantial burden to patients’ quality of life so effective treatment strategies are required to manage this problem. Varicose vein surgery has been performed for many years but medium- and long-term outcome studies of modern surgery show that recurrence is a common problem.<sup><xref ref-type="bibr" rid="bibr1-phleb.2012.012051">1</xref></sup> New and less invasive treatments have been developed over the last two decades. Thermal ablation of varicose veins using endovenous laser or radiofrequency ablation show promising results on mid-term follow-up.<sup><xref ref-type="bibr" rid="bibr2-phleb.2012.012051">2</xref>,<xref ref-type="bibr" rid="bibr3-phleb.2012.012051">3</xref></sup> Injection sclerotherapy for varicose veins was first described in the 19th century and is widely used today. The modern development of ultrasound-guided foam sclerotherapy has extended the efficacy of this treatment to large saphenous trunks and varices.<sup><xref ref-type="bibr" rid="bibr4-phleb.2012.012051">4</xref>–<xref ref-type="bibr" rid="bibr6-phleb.2012.012051">6</xref></sup> These minimally invasive techniques allow outpatient treatment of varicose veins with few postoperative sequelae. Serious adverse events (AEs) are rare.<sup><xref ref-type="bibr" rid="bibr2-phleb.2012.012051">2</xref>,<xref ref-type="bibr" rid="bibr3-phleb.2012.012051">3</xref>,<xref ref-type="bibr" rid="bibr7-phleb.2012.012051">7</xref></sup> However, patients undergoing treatment with foam sclerotherapy sometimes report visual disturbance (VD) immediately following treatment. The character of these events appears to be heterogeneous and, for example, may be described as uni- and bilateral, blurred vision, doubled vision or scotoma. Moreover, a small number of case reports have associated sclerotherapy with serious neurological events including transient ischaemic attacks and reversible ischaemic neurological deficit.<sup><xref ref-type="bibr" rid="bibr8-phleb.2012.012051">8</xref></sup> This type of AE has also been reported following thermal ablation techniques and saphenous vein stripping.<sup><xref ref-type="bibr" rid="bibr9-phleb.2012.012051">9</xref>,<xref ref-type="bibr" rid="bibr10-phleb.2012.012051">10</xref></sup> In contrast, VD appear to be strongly associated with sclerotherapy and may be considered the most prevalent systemic side-effect of foam sclerotherapy.</p>
<p>A number of different mechanisms may be responsible for systemic complications following sclerotherapy. Micro bubbles may trigger embolic events. Some authors suggest that liberation of biological mediators as a result of detergent sclerosant action could cause vasoconstriction and hence transient ischaemic symptoms such as VD.<sup><xref ref-type="bibr" rid="bibr11-phleb.2012.012051">11</xref></sup> Even if the overall prevalence of these systemic side-effects is low and sclerotherapy is considered to be a safe treatment option for varicose veins, further research is required in order to maximize the safety of sclerotherapy.</p>
<p>As VD appear to be a specific systemic side-effects following sclerotherapy, we aim to analyse and summarize the available published literature reporting this event and discuss the underlying mechanisms.</p>
</sec>
<sec id="sec2-phleb.2012.012051" sec-type="methods"><title>Methods</title>
<p>A systematic search of electronic databases (PubMed Mesh and Google Scholar) was conducted. All papers reporting VD associated with sclerotherapy for varicose veins were included. Searches were not restricted by language or publication year. Database searches were augmented by hand searching of journals not consistently indexed in the major databases (particularly ‘Phlebologie’ (Germany) and ‘Phlébologie’ (France).</p>
<p>Figure <xref ref-type="fig" rid="fig1-phleb.2012.012051">1</xref> illustrates the literature search and the yielded results. Based on the title and abstract of the publication, articles containing clinical data on the complications of sclerotherapy were reviewed in detail and all papers reporting VD were selected. The ‘related articles’ function was utilized to broaden the search and all abstracts, studies and citations were reviewed for each selected publication. References of the articles acquired were also searched manually. The latest date for this search was November 2011. The quality of each selected paper was assessed and extracted the following data: author, year of publication, type of publication, number of cases treated, number of VD reported, type and concentration of sclerosant used, applied volume, mode of foam preparation including production technique, gas used to produce the foam, gas/liquid ratio, kind varicose vein treated, quality of VD such as time of occurrence related to sclerotherapy, unilateral or bilateral affection, duration of the event and accompanying symptoms. All chosen articles were re-examined jointly and appropriate corrections made. To identify duplicate reporting of the same cohort of patients, the authorship of all papers was cross-referenced.
<fig id="fig1-phleb.2012.012051"><label>Figure 1</label><caption><p>Search terms and yielded results</p></caption>
<graphic xlink:href="10.1258_phleb.2012.012051-fig1.tif"/>
</fig></p>
<sec id="sec2a"><title>Inclusion and exclusion criteria</title>
<p>Any article reporting on VD after sclerotherapy for the treatment of varicose veins was included. No other specific exclusion criteria were defined.</p>
</sec>
</sec>
<sec id="sec3-phleb.2012.012051" sec-type="results"><title>Results</title>
<p>Tables <xref ref-type="table" rid="table1-phleb.2012.012051">1</xref> and <xref ref-type="table" rid="table2-phleb.2012.012051">2</xref> show all identified papers reporting VD and give details on the reported events.
<table-wrap id="table1-phleb.2012.012051" position="float"><label>Table 1</label><caption><p>Randomized controlled trials yielded at literature research are listed</p></caption>
<graphic alternate-form-of="table1-phleb.2012.012051" xlink:href="10.1258_phleb.2012.012051-table1.tif"/>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="left">Design</th>
<th align="left">Number of patients</th>
<th align="left">Number of sessions</th>
<th align="left">Number of VD</th>
<th align="left">Type of vein</th>
<th align="left">Time of appearance after therapy</th>
<th align="left">Unilateral/bilateral</th>
<th align="left">Sclerosant, concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kern P, 2004</td>
<td>RCT</td>
<td>150</td>
<td>1</td>
<td>3</td>
<td>Teleangiectasia and reticular veins</td>
<td>Nr</td>
<td>Bilateral</td>
<td>POL, 0.25%</td>
</tr>
<tr>
<td>Morrison N, 2008</td>
<td>RCT</td>
<td>177 (49/128)</td>
<td>177</td>
<td>8</td>
<td>All kinds of refluxing veins</td>
<td>Nr</td>
<td>Nr</td>
<td>POL, 1%</td>
</tr>
<tr>
<td>Alos J, 2006</td>
<td>RCT</td>
<td>75</td>
<td>150</td>
<td>0</td>
<td>Reticular veins, tributaries</td>
<td>–</td>
<td>–</td>
<td>POL, 0.5–1.25%</td>
</tr>
<tr>
<td>Ouvry P, 2008</td>
<td>RCT</td>
<td>95</td>
<td>95</td>
<td>0</td>
<td>GSV</td>
<td>–</td>
<td>–</td>
<td>POL, 3%</td>
</tr>
</tbody>
</table>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Foam/liquid</th>
<th align="left">Foam preparation</th>
<th align="left">Type of gas</th>
<th align="left">Volume of foam/liquid (average or maximum)</th>
<th align="left">Liquid/air</th>
<th align="left">Additional symptoms beside visual disturbances</th>
</tr>
</thead>
<tbody>
<tr>
<td>3F/0L</td>
<td>MUS</td>
<td>Air</td>
<td>Maximum 10 mL</td>
<td>Nr</td>
<td>None</td>
</tr>
<tr>
<td>F</td>
<td>Tessari</td>
<td>Air or Air/CO<sub>2</sub></td>
<td>Air 27 mL ± 10 Air/CO<sub>2</sub> 25 ± 12</td>
<td>1:4</td>
<td>Nr</td>
</tr>
<tr>
<td>F/L</td>
<td>Tessari</td>
<td>Air</td>
<td>Foam 2 mL Liquid 0.5 mL</td>
<td>1:4</td>
<td>Nr</td>
</tr>
<tr>
<td>F/L</td>
<td>DSS</td>
<td>Air</td>
<td>2–2.5 mL</td>
<td>1:4</td>
<td>Nr</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-phleb.2012.012051"><p>RCT, randomized controlled trial; VD, visual disturbances; Nr, not reported; POL, polidocanol; DSS, double-syringe technique; MUS, Monfreux technique; GSV, great saphenous vein; F, foam; L, Liquid</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-phleb.2012.012051" position="float"><label>Table 2</label><caption><p>All case series reporting visual disturbances and dedicated case reports on visual disturbances detected by literature research</p></caption>
<graphic alternate-form-of="table2-phleb.2012.012051" xlink:href="10.1258_phleb.2012.012051-table2.tif"/>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Author, Year</th>
<th align="left">Design</th>
<th align="left">Number<break/>of patents</th>
<th align="left">Number<break/>of sessions</th>
<th align="left">Number<break/>of VD</th>
<th align="left">Time of<break/>appearance<break/>after therapy</th>
<th align="left">Unilateral/<break/>bilateral</th>
<th align="left">Sclerosant,<break/>concentration</th>
<th align="left">Foam/<break/>liquid</th>
<th align="left">Foam<break/>preparation</th>
<th align="left">Liquid/<break/>air</th>
</tr>
</thead>
<tbody>
<tr>
<td>Henriet JP, 1999</td>
<td>Series</td>
<td>10,263</td>
<td>Nr</td>
<td>9</td>
<td>Immediately</td>
<td>Nr</td>
<td>Nr</td>
<td>F</td>
<td>Monfreux</td>
<td>1:4</td>
</tr>
<tr>
<td>Tessari L, 2001</td>
<td>Series</td>
<td>77</td>
<td>Nr</td>
<td>2</td>
<td>Nr</td>
<td>Nr</td>
<td>STS</td>
<td>F</td>
<td>Tessari</td>
<td>1:4</td>
</tr>
<tr>
<td>Frullini A, 2002</td>
<td>Series</td>
<td>257</td>
<td>1.8</td>
<td>3</td>
<td>Nr</td>
<td>Nr</td>
<td>POL/STS, Nr</td>
<td>F</td>
<td>MUS</td>
<td>Nr</td>
</tr>
<tr>
<td>Frullini A*, 2002</td>
<td>Series</td>
<td>196</td>
<td>1.8</td>
<td>1</td>
<td>Nr</td>
<td>Nr</td>
<td>POL/STS, Nr</td>
<td>F</td>
<td>Tessari</td>
<td>Nr</td>
</tr>
<tr>
<td>Cavezzi A, 2002</td>
<td>Series</td>
<td>194</td>
<td>1.6</td>
<td>1</td>
<td>Nr</td>
<td>Nr</td>
<td>STS, Nr</td>
<td>F</td>
<td>Tessari</td>
<td>1:4–5</td>
</tr>
<tr>
<td>Cabrera J, 2001</td>
<td>Series</td>
<td>711</td>
<td>Nr</td>
<td>1%</td>
<td>Nr</td>
<td>Nr</td>
<td>POL MF</td>
<td>F</td>
<td>MF</td>
<td>Nr</td>
</tr>
<tr>
<td>Cabrera J, 2004</td>
<td>Series</td>
<td>116</td>
<td>3.6</td>
<td>2</td>
<td>Nr</td>
<td>Nr</td>
<td>POL MF</td>
<td>F</td>
<td>MF</td>
<td>Nr</td>
</tr>
<tr>
<td>Guexx JJ, 2005</td>
<td>Series</td>
<td>Nr</td>
<td>12,173</td>
<td>20</td>
<td>Immediately</td>
<td>Nr</td>
<td>Nr</td>
<td>19 F/1L</td>
<td>Nr</td>
<td>Nr</td>
</tr>
<tr>
<td>Bergan J, 2006</td>
<td>Series</td>
<td>332</td>
<td>Nr</td>
<td>3</td>
<td>Immediately</td>
<td>Nr</td>
<td>POL, Nr</td>
<td>F/L (ns)</td>
<td>Tessari</td>
<td>1:3</td>
</tr>
<tr>
<td>Darke SG, 2006</td>
<td>Series</td>
<td>181</td>
<td>197</td>
<td>3</td>
<td>5 minutes</td>
<td>Nr</td>
<td>POL 1%</td>
<td>F</td>
<td>Tessari</td>
<td>1:3</td>
</tr>
<tr>
<td>Künzlberger B,<break/>2006</td>
<td>Case</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>5 minutes</td>
<td>Unilateral</td>
<td>POL 1%</td>
<td>L</td>
<td>Nr</td>
<td>Nr</td>
</tr>
<tr>
<td>Smith PC, 2006</td>
<td>Series</td>
<td>808</td>
<td>Nr</td>
<td>14</td>
<td>Immediately</td>
<td>Nr</td>
<td>POL/STS 1–3%</td>
<td>F</td>
<td>Tessari</td>
<td>1:3</td>
</tr>
<tr>
<td>Wright D, 2006</td>
<td>Series</td>
<td>437</td>
<td>Nr</td>
<td>6</td>
<td>Nr</td>
<td>Nr</td>
<td>POL MF</td>
<td>F</td>
<td>MF</td>
<td>Nr</td>
</tr>
<tr>
<td>Myers K, 2007</td>
<td>Series</td>
<td>489</td>
<td>1189</td>
<td>3</td>
<td>Immediately</td>
<td>Nr</td>
<td>POL/STS, Nr</td>
<td>F/L (ns)</td>
<td>Tessari</td>
<td>2:3</td>
</tr>
<tr>
<td>Bhogal R, 2008</td>
<td>Series</td>
<td>112</td>
<td>Nr</td>
<td>1</td>
<td>Nr</td>
<td>Nr</td>
<td>Nr</td>
<td>F</td>
<td>Nr</td>
<td>Nr</td>
</tr>
<tr>
<td>Martimbeau PR,<break/>2008</td>
<td>Series</td>
<td>3259</td>
<td>4891</td>
<td>2</td>
<td>Immediately</td>
<td>Nr</td>
<td>STS, 0,5–3%</td>
<td>F</td>
<td>DSS</td>
<td>1:4</td>
</tr>
<tr>
<td>Ceulen RPM,<break/>2008</td>
<td>Case</td>
<td>1</td>
<td>1</td>
<td>Nr</td>
<td>Immediately</td>
<td>Bilateral</td>
<td>Nr</td>
<td>F</td>
<td>Nr</td>
<td>Nr</td>
</tr>
<tr>
<td>Hartmann K,<break/>2009</td>
<td>Case</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Immediately</td>
<td>Nr</td>
<td>POL, 3%</td>
<td>F</td>
<td>DSS</td>
<td>1:4</td>
</tr>
<tr>
<td>Gillet JL, 2009</td>
<td>Series</td>
<td>1025</td>
<td>Nr</td>
<td>18</td>
<td>Immediately</td>
<td>Nr</td>
<td>POL/STS</td>
<td>F</td>
<td>Tessari/DSS</td>
<td>1:1–1:5</td>
</tr>
<tr>
<td>Park SW, 2009</td>
<td>Series</td>
<td>312</td>
<td>1</td>
<td>1</td>
<td>Immediately</td>
<td>Nr</td>
<td>POL, 1%</td>
<td>F</td>
<td>Tessari</td>
<td>1:5</td>
</tr>
<tr>
<td>Bradbury A,<break/>2010</td>
<td>Series</td>
<td>977</td>
<td>Nr</td>
<td>5</td>
<td>Immediately</td>
<td>Nr</td>
<td>STS, 1–3%</td>
<td>F</td>
<td>Tessari</td>
<td>1:4</td>
</tr>
</tbody>
</table>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left">Author,<break/>Year</th>
<th align="left">Type of<break/>vein</th>
<th align="left">Type<break/>of gas</th>
<th align="left">Volume of foam/liquid</th>
<th align="left">Additional symptoms beside<break/>visual disturbances</th>
</tr>
</thead>
<tbody>
<tr>
<td>Henriet JP, 1999</td>
<td>Reticular and threat veins</td>
<td>Air</td>
<td>Maximum 2.5–5 mL</td>
<td>Nr</td>
</tr>
<tr>
<td>Tessari L, 2001</td>
<td>All kinds</td>
<td>Air</td>
<td>2–8 mL</td>
<td>Nr</td>
</tr>
<tr>
<td>Frullini A, 2002</td>
<td>All kinds</td>
<td>Air</td>
<td>Maximum 4 mL</td>
<td>Nr</td>
</tr>
<tr>
<td>Frullini A*, 2002</td>
<td>All kinds</td>
<td>Air</td>
<td>Mean 2.7</td>
<td>Nr</td>
</tr>
<tr>
<td>Cavezzi A, 2002</td>
<td>Trunk varices and tributaries</td>
<td>Air</td>
<td>Mean 2.9–3.2</td>
<td>Nr</td>
</tr>
<tr>
<td>Cabrera J, 2001</td>
<td>Trunk varices and tributaries</td>
<td>Air</td>
<td>Nr</td>
<td>Nr</td>
</tr>
<tr>
<td>Cabrera J, 2004</td>
<td>Trunk varices and tributaries</td>
<td>Air</td>
<td>Maximum 30</td>
<td>Nr</td>
</tr>
<tr>
<td>Guexx JJ, 2005</td>
<td>All kinds</td>
<td>Air</td>
<td>Nr</td>
<td>Nr</td>
</tr>
<tr>
<td>Bergan J, 2006</td>
<td>All kinds except teleangiectasias</td>
<td>Air</td>
<td>Nr</td>
<td>Nr</td>
</tr>
<tr>
<td>Darke SG, 2006</td>
<td>Trunk and tributaries</td>
<td>Air</td>
<td>Maximum 14</td>
<td>1 chest discomfort in<break/>same interval as VD</td>
</tr>
<tr>
<td>Künzlberger B,<break/>2006</td>
<td>Threat veins</td>
<td>Air</td>
<td>Nr</td>
<td>Dizziness</td>
</tr>
<tr>
<td>Smith PC, 2006</td>
<td>Trunk and tributaries</td>
<td>Air</td>
<td>Median over all sessions 14</td>
<td>Nr</td>
</tr>
<tr>
<td>Wright D, 2006</td>
<td>Trunk and tributaries</td>
<td>Air</td>
<td>Foam mean 9.8 Liquid mean 3.5</td>
<td>Nr</td>
</tr>
<tr>
<td>Myers K, 2007</td>
<td>Trunk and tributaries</td>
<td>Air</td>
<td>Median 5 (range 3–40)</td>
<td>None</td>
</tr>
<tr>
<td>Bhogal R, 2008</td>
<td>Trunk and tributaries</td>
<td>Nr</td>
<td>Mean 17.5</td>
<td>Nr</td>
</tr>
<tr>
<td>Martimbeau PR,<break/>2008</td>
<td>All kinds</td>
<td>Air</td>
<td>0.5–8 mL</td>
<td>Nr</td>
</tr>
<tr>
<td>Ceulen RPM,<break/>2008</td>
<td>Nr</td>
<td>Nr</td>
<td>Nr</td>
<td>Nr</td>
</tr>
<tr>
<td>Hartmann K,<break/>2009</td>
<td>Trunk varices</td>
<td>Air</td>
<td>9 mL</td>
<td>Speech disturbance</td>
</tr>
<tr>
<td>Gillet JL, 2009</td>
<td>Trunk varices</td>
<td>Air</td>
<td>Mean 4.5</td>
<td>4 with head ache 5 with<break/>chest pain</td>
</tr>
<tr>
<td>Park SW, 2009</td>
<td>Trunk varices tributaries</td>
<td>Air</td>
<td>2–13</td>
<td>Nr</td>
</tr>
<tr>
<td>Bradbury A, 2010</td>
<td>Trunk varices tributaries</td>
<td>Air</td>
<td>2–17</td>
<td>None</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-phleb.2012.012051"><p>VD, visual disturbances; Nr, not reported; ns, not specified; STS, sodium tetdradecyl sulphate; POL, polidocanol; POL MF, polidocanol microfoam (Varisolve<sup>®</sup>); DSS, double-syringe technique; MUS, Monfreux technique; F, foam; L, liquid</p></fn>
</table-wrap-foot>
</table-wrap></p>
<sec id="sec3a"><title>Reports yielded by literature research</title>
<p>A total number of 4948 results were yielded by the search. There were 34 reporting systemic and neurological side-effects following sclerotherapy of varicose veins. We identified 25 publications reporting VD following sclerotherapy.<sup><xref ref-type="bibr" rid="bibr4-phleb.2012.012051">4</xref>,<xref ref-type="bibr" rid="bibr12-phleb.2012.012051">12</xref>–<xref ref-type="bibr" rid="bibr34-phleb.2012.012051">34</xref></sup> Most of the reports were case series (18), there were four randomized trials and three case reports.</p>
</sec>
<sec id="sec3b"><title>Not included reports</title>
<p>Reports about sclerotherapy for varicose veins that did not mention VDs were not included in the analysis. For example, the EASY or the ESAF study did not mention any visual side-effects, but neither clearly expressed if they were investigated or not.<sup><xref ref-type="bibr" rid="bibr35-phleb.2012.012051">35</xref>,<xref ref-type="bibr" rid="bibr36-phleb.2012.012051">36</xref></sup> In this case we could not conclude that no VD had occurred. Data of these studies were not considered for further analyses.</p>
</sec>
<sec id="sec3c"><title>Type of varicosity treated</title>
<p>VDs were reported following sclerotherapy for all kinds of varicosity. However, the majority of reports (13 of 25) were describing treatment of trunk varicies and tributaries. Three of 25 studies mentioned the exclusive sclerotherapy of teleangiectasias and reticular veins in association with VD.</p>
</sec>
<sec id="sec3d"><title>Prevalence of VD following sclerotherapy for varicose veins</title>
<p>The overall prevalence of VD cannot be determined from the reviewed data because it was not always clear as to whether VD were reported per patient or per treatment session. Some reports did not mention VD as a side-effect which does not allow any conclusion as to whether there were none or they have not been investigated.<sup><xref ref-type="bibr" rid="bibr35-phleb.2012.012051">35</xref>–<xref ref-type="bibr" rid="bibr41-phleb.2012.012051">41</xref></sup></p>
</sec>
<sec id="sec3e"><title>Prevalence in randomized controlled trials</title>
<p>Four randomized controlled trials reporting VD associated with sclerotherapy were identified (Table <xref ref-type="table" rid="table1-phleb.2012.012051">1</xref>).<sup><xref ref-type="bibr" rid="bibr21-phleb.2012.012051">21</xref>,<xref ref-type="bibr" rid="bibr22-phleb.2012.012051">22</xref>,<xref ref-type="bibr" rid="bibr32-phleb.2012.012051">32</xref>,<xref ref-type="bibr" rid="bibr33-phleb.2012.012051">33</xref></sup> One included 177 patients undergoing one session of sclerotherapy and comparing air-based and CO<sub>2</sub>-based foam sclerosant for therapeutic side-effects, reported a prevalence of the whole study cohort of 4.5%.<sup><xref ref-type="bibr" rid="bibr22-phleb.2012.012051">22</xref></sup> However, in the group treated with CO<sub>2</sub>-based foam the prevalence was 3.1% while in the air-based foam group it was 8.2% (<italic>P</italic> = 0.15). Patients reported VD in this study received large volumes of air-based foam (≥15 mL). Another randomized trial compared pure chromated glycerine, polidocanol (POL) 0.25% solution and POL 0.25% foam (Monfreux technique [MUS]) for the treatment of telangiectatic leg veins.<sup><xref ref-type="bibr" rid="bibr21-phleb.2012.012051">21</xref></sup> In this trial 150 patients were randomized of whom three experienced bilateral VD following sclerotherapy, all three following injection of POL 0.25% foam produced by the MUS. The third randomized controlled trial was comparing foam and liquid sclerotherapy for the treatment of the great saphenous vein. Ninety-five patients were randomized to either liquid or foam sclerotherapy (2–2.5 mL of 3% POL liquid or foam). The authors report no case of VD in either group.<sup><xref ref-type="bibr" rid="bibr33-phleb.2012.012051">33</xref></sup> Likewise, no VD was observed in another randomized trial including 75 patients (150 treatment sessions) and comparing efficacy and safety of POL foam and liquid.<sup><xref ref-type="bibr" rid="bibr32-phleb.2012.012051">32</xref></sup></p>
</sec>
<sec id="sec3f"><title>Prevalence in case series and case reports</title>
<p>We identified 18 case series reporting the prevalence of VD and three dedicated case reports. In larger series including at least 500 patients the prevalence ranged from 0.09% to 2%.<sup><xref ref-type="bibr" rid="bibr4-phleb.2012.012051">4</xref>,<xref ref-type="bibr" rid="bibr14-phleb.2012.012051">14</xref>,<xref ref-type="bibr" rid="bibr20-phleb.2012.012051">20</xref>,<xref ref-type="bibr" rid="bibr25-phleb.2012.012051">25</xref>,<xref ref-type="bibr" rid="bibr26-phleb.2012.012051">26</xref>,<xref ref-type="bibr" rid="bibr30-phleb.2012.012051">30</xref>,<xref ref-type="bibr" rid="bibr31-phleb.2012.012051">31</xref>,<xref ref-type="bibr" rid="bibr42-phleb.2012.012051">42</xref></sup> All case series and case reports yielded by our research are listed in Table <xref ref-type="table" rid="table2-phleb.2012.012051">2</xref>.</p>
</sec>
<sec id="sec3g"><title>Sclerosants</title>
<p>When reported, POL and sodium tetradecyl sulphate (STS) were used for sclerotherapy. In two of the reports pure liquid sclerosant has been used.<sup><xref ref-type="bibr" rid="bibr42-phleb.2012.012051">42</xref>,<xref ref-type="bibr" rid="bibr43-phleb.2012.012051">43</xref></sup> One is a case report and the second derives from a French registry report.<sup><xref ref-type="bibr" rid="bibr42-phleb.2012.012051">42</xref>,<xref ref-type="bibr" rid="bibr43-phleb.2012.012051">43</xref></sup> In this registry 20 events of VD are mentioned in a series of 12,173 sessions, one of them after liquid sclerosant, 16 after foam and three after liquid sclerosant injected using the air block technique.<sup><xref ref-type="bibr" rid="bibr42-phleb.2012.012051">42</xref></sup> Two other papers reporting VD did not specify the use of either liquid or foam.<sup><xref ref-type="bibr" rid="bibr12-phleb.2012.012051">12</xref>,<xref ref-type="bibr" rid="bibr23-phleb.2012.012051">23</xref></sup> However, in one of these studies 98 out of 1189 patients (8%) were treated with liquid sclerosant while all other patients were treated with STS and POL foam.<sup><xref ref-type="bibr" rid="bibr23-phleb.2012.012051">23</xref></sup> The second report by Wright <italic>et al.</italic><sup><xref ref-type="bibr" rid="bibr28-phleb.2012.012051">28</xref></sup> mentioned six patients with transient neurological symptoms occurring within 24 h of treatment including paraesthesiae, visual and speech disorders. In this series, 92% of 710 patients were treated with foam (POL) and 8% received liquid sclerotherapy. There are several papers (not listed in the tables) where authors reported their personnel experience of VD following sclerotherapy with liquid sclerosant.<sup><xref ref-type="bibr" rid="bibr11-phleb.2012.012051">11</xref>,<xref ref-type="bibr" rid="bibr44-phleb.2012.012051">44</xref></sup></p>
</sec>
<sec id="sec3h"><title>Technique of foam preparation</title>
<p>Technique of foam preparation was not always reported. Several different methods of foam preparation were applied. The Tessari method was named 11 times, in one report Tessari and the double-syringe technique were mentioned without further specification. There are two other reports describing the double-syringe technique for foam preparation. MUS was mentioned by Kern <italic>et al</italic>.<sup><xref ref-type="bibr" rid="bibr21-phleb.2012.012051">21</xref></sup> when reporting three events of VD in a prospective trial which also included the use of liquid sclerosants (POL and pure chromated glycerine). Three reports mentioned the use of POL micro foam (Varisolve<sup>®</sup>, BTG - British Technology Group, London, UK).</p>
</sec>
<sec id="sec3i"><title>Gas and volume of sclerosant</title>
<p>In most reports air was used to produce the foam (22 of 25). As far as determinable the applied volume was very heterogeneous with a wide range from 2 to 40 mL. In most reports there is no information about the exact volume applied during the treatment session associated with VD. Morrison <italic>et al.</italic><sup><xref ref-type="bibr" rid="bibr22-phleb.2012.012051">22</xref></sup> found in their prospective randomized trial that the event probability for VD tends to a significant increase after an applied volume of 15–16 mL of foam.</p>
</sec>
<sec id="sec3j"><title>Character of VD</title>
<p>There was no explicit report of persistent VD. VD events occurred most often immediately or after a maximum of five minutes following sclerotherapy.</p>
<p>VDs were described to be bilateral in three patients when reported by Kern <italic>et al.</italic> and in one patient mentioned in a case report by Ceulen <italic>et al</italic>.<sup><xref ref-type="bibr" rid="bibr16-phleb.2012.012051">16</xref>,<xref ref-type="bibr" rid="bibr21-phleb.2012.012051">21</xref></sup> In his series, Gillet reported that VD involved one eye in 35% of patients and two eyes in 65%.<sup><xref ref-type="bibr" rid="bibr34-phleb.2012.012051">34</xref></sup> Apart from one case report, where VD were described as unilateral, all other reported VDs were not further specified as unilateral or bilateral.<sup><xref ref-type="bibr" rid="bibr43-phleb.2012.012051">43</xref></sup></p>
</sec>
</sec>
<sec id="sec4-phleb.2012.012051" sec-type="discussion"><title>Discussion</title>
<p>We identified 25 reports concerning VD following sclerotherapy, most of them associated with foam sclerotherapy. The prevalence of VD differs significantly between reports and ranges from 0.09% to 2% in the larger case series including at least 500 patients and from 0% to 4.5% in prospective randomized controlled trials. Certainly, the true prevalence of VD remains unclear. There are other studies and series where the authors do not report VD after sclerotherapy; however, these may have been missed as they were not especially investigated. Morrison <italic>et al.</italic><sup><xref ref-type="bibr" rid="bibr22-phleb.2012.012051">22</xref></sup> found in his prospective survey that the amount of sclerosant foam used might play a key role in the prevalence of systemic side-effects like VD. In their study only patients who received more than 15–16 mL of foam were subjects to systemic side-effects including VD. Most of the literature we reviewed did not provide detailed information about the amount of sclerosant injected in patients who experienced VD following sclerotherapy. However, as there are substantial differences in the techniques used among specialists, including the volumes of sclerosants injected per session, it is possible that this may account for the differences observed in the prevalence of VD.</p>
<p>The majority of VDs occurred following the use of foam sclerotherapy with STS and POL. There are fewer but valid reports of VD following liquid sclerotherapy, two cases were identified in this review. Some experts mentioned their personal experience of liquid sclerotherapy triggering VD on some occasions.<sup><xref ref-type="bibr" rid="bibr11-phleb.2012.012051">11</xref>,<xref ref-type="bibr" rid="bibr46-phleb.2012.012051">46</xref></sup> Apart from this, the detailed review of all reported events included in our paper does not reveal any additional triggering factor related to the technique used in foam preparation, the air/liquid ratio, the sclerosant or its concentration. Remarkably, the first case series found in our research reporting VD was published in 1999. However, we can stipulate that side-effects, such as VD, are more carefully investigated in recent studies compared with the past. Nevertheless, sclerotherapy has been performed since the first half of the 19th century and it is interesting that apart from some personal experiences, no earlier reports of this systemic complication have been published.<sup><xref ref-type="bibr" rid="bibr47-phleb.2012.012051">47</xref>,<xref ref-type="bibr" rid="bibr48-phleb.2012.012051">48</xref></sup> This suggests that modern foam sclerotherapy, which was introduced in 1994,<sup><xref ref-type="bibr" rid="bibr49-phleb.2012.012051">49</xref></sup> triggers these side-effects to a greater extent than liquid sclerotherapy.</p>
<sec id="sec4a"><title>Mechanism of VD</title>
<p>The mechanism of VD appears to be that of migraine with aura, according to several authors who have carefully considered the available clinical data.<sup><xref ref-type="bibr" rid="bibr20-phleb.2012.012051">20</xref>,<xref ref-type="bibr" rid="bibr25-phleb.2012.012051">25</xref>,<xref ref-type="bibr" rid="bibr34-phleb.2012.012051">34</xref></sup> VD following sclerotherapy usually arises in patients with a history of migraine with aura. Gillet <italic>et al</italic>.<sup><xref ref-type="bibr" rid="bibr34-phleb.2012.012051">34</xref></sup> carried out a prospective study including patients who had experienced transient VD after foam sclerotherapy. The authors concluded that VD following foam sclerotherapy correspond to migraine with aura and are not transient ischaemic cerebrovascular events.</p>
<p>The neurophysiological mechanism for migraine is cortical spreading depression.<sup><xref ref-type="bibr" rid="bibr50-phleb.2012.012051">50</xref></sup> It is known as a slow depolarization of the cortex and can be assessed by functional magnetic resonance imaging or electrocorticogram. There is evidence that some biological mediators may trigger this event in susceptible patients.<sup><xref ref-type="bibr" rid="bibr11-phleb.2012.012051">11</xref></sup> A mechanism in which sclerotherapy induces the release of those mediators from the treated endothelium resulting in VD has been suggested.<sup><xref ref-type="bibr" rid="bibr11-phleb.2012.012051">11</xref></sup></p>
<p><italic>In vivo</italic> studies show that STS and POL lead to an immediate damage of the venous wall after exposure to the sclerosant.<sup><xref ref-type="bibr" rid="bibr38-phleb.2012.012051">38</xref>,<xref ref-type="bibr" rid="bibr51-phleb.2012.012051">51</xref></sup> This reaction appears to be augmented with foam sclerosants in comparison with liquid.<sup><xref ref-type="bibr" rid="bibr38-phleb.2012.012051">38</xref></sup> Endothelial cell lyses could lead to an immediate release of intracellular mediators such as endothelin. Endothelin is known as a very strong vasoconstrictor.<sup><xref ref-type="bibr" rid="bibr52-phleb.2012.012051">52</xref></sup> Endothelin 1 is thought to trigger cortical spreading depression, a suggestion supported by animal studies.<sup><xref ref-type="bibr" rid="bibr53-phleb.2012.012051">53</xref></sup> However, also other mediators are released by sclerosants and in particular procoagulant platelet-derived microparticles, adhesion molecules such as P-selectin, neurotransmittors such as serotonin, all of which can induce vasoconstriction and may have a role in the pathogenesis of migraine and VDs.<sup><xref ref-type="bibr" rid="bibr54-phleb.2012.012051">54</xref></sup></p>
<p>The frequency of Persistent Foramen Ovale (PFO) in the general population has been estimated at 26% based on an autopsy study.<sup><xref ref-type="bibr" rid="bibr55-phleb.2012.012051">55</xref></sup> The presence of a patent foramen ovale is suggested to be more common in patients with varicose veins and may lead to gas bubbles entering the systemic circulation following foam sclerotherapy.<sup><xref ref-type="bibr" rid="bibr56-phleb.2012.012051">56</xref></sup> However, a detailed examination of the brain using magnetic resonance imaging scanning following foam sclerotherapy using ultra-low nitrogen foam showed no evidence of the development of cerebral lesions.<sup><xref ref-type="bibr" rid="bibr57-phleb.2012.012051">57</xref></sup></p>
<p>Hansen <italic>et al</italic>.<sup><xref ref-type="bibr" rid="bibr58-phleb.2012.012051">58</xref></sup> undertook transcutaneous ultrasound, transthoracic ultrasound and transcranial Doppler ultrasound (TCD) studies in 20 patients suspected of having symptoms which might be attributable to a patent foramen ovale and who were undergoing ultrasound-guided foam sclerotherapy for varicose veins. In this study, the proportion of AEs was similar in the seven patients without left heart bubbles compared with the 13 patients with left heart bubbles. It is clear that the left heart bubbles commonly reach the cerebral circulation and four of five patients in which this was shown reported any symptom. This paper indicates that bubbles reaching the left heart via a patent foramen ovale often find their way to the cerebral circulation. However, it appears that some patients with symptoms had no left heart bubbles. Raymond-Martimbeau<sup><xref ref-type="bibr" rid="bibr25-phleb.2012.012051">25</xref></sup> prospectively studied the association between a patent foramen ovale and transient AEs reported by patients after ultrasound-guided foam sclerotherapy for varicose veins. Seven of 3259 patients (0.21%) reported transient AEs included VD, migraine and chest discomfort. Five of these seven patients tested positive for PFO by Transcranial Doppler (cTCD).</p>
<p>The studies described above show that systemic embolism of small numbers of bubbles is a common event after foam sclerotherapy but this does not necessarily have a direct relationship to VD. VD following foam sclerotherapy is more probably attributable to migraine with aura, a benign condition, and not to any embolic problem associated with the bubbles. There is no evidence that this leads to any long-term damage to the central nervous system.</p>
</sec>
<sec id="sec4b"><title>Preventive measures</title>
<p>Some preventive measures to reduce VD and other systemic side-effects of sclerotherapy have been proposed without any scientific evidence. Experts suggest avoiding manoeuvres such as bending over to put on shoes or compression stockings and remaining supine following injections of foam for approximately five minutes may reduce the risk.<sup><xref ref-type="bibr" rid="bibr59-phleb.2012.012051">59</xref></sup> In addition, Morrison <italic>et al</italic>. suggested that the solubility of the gas used to create the foam may have an effect on the prevalence of systemic side-effects. CO<sub>2-</sub>based gas is thought to cause less systemic side-effects including VD. The rationale behind this suggestion is that air mixture, containing high percentages of relatively insoluble nitrogen, is replaced with CO<sub>2</sub>, which is highly soluble in blood. As mentioned above, in one study this has been shown to reduce the incidence of VD.<sup><xref ref-type="bibr" rid="bibr22-phleb.2012.012051">22</xref></sup> However, in a recent German study, no difference was noted between air and CO<sub>2</sub>-O<sub>2</sub>-based foam.<sup><xref ref-type="bibr" rid="bibr60-phleb.2012.012051">60</xref></sup></p>
<p>It has been suggested that patients with a history of migraine are especially at risk of developing VD after sclerotherapy.<sup><xref ref-type="bibr" rid="bibr34-phleb.2012.012051">34</xref></sup> However, sclerotherapy may be considered safe even in migraine patients. These patients should be thoroughly well informed and consented prior to the treatment. The same is applicable for patients with a patent foramen ovale. A volume limitation of 10 mL per session might be advised to be respected in these patients according to the experts’ guidelines.<sup><xref ref-type="bibr" rid="bibr59-phleb.2012.012051">59</xref></sup> Although the total volume is important, where and how this volume is injected could very likely make a difference. For example, injecting 10 mL at the saphenofemoral junction is a different procedure to injecting 10 mL along the entire length of the saphenous system. As referred to Parsi,<sup><xref ref-type="bibr" rid="bibr61-phleb.2012.012051">61</xref></sup> even a small volume of 1.5 mL injected distally can result in appearance of bubbles in the heart. In this study, venous gas embolism could not be avoided by several manoeuvres including the use of microfilters, CO<sub>2</sub> as the foaming gas, leg elevation or post-treatment immobilization.<sup><xref ref-type="bibr" rid="bibr61-phleb.2012.012051">61</xref></sup> However, technique modifications should be further investigated and aim to reduce the systematic dissemination of foam, irrespective of the total volume.</p>
</sec>
</sec>
<sec id="sec5-phleb.2012.012051" sec-type="conclusions"><title>Conclusion</title>
<p>VD following sclerotherapy for varicose veins is an uncommon event. Echocardiography and transcranial Doppler assessment show that all patients undergoing foam sclerotherapy experience bubble embolism to the right heart. Some of those with a patent foramen ovale show embolization to the systemic circulation. There is no direct relationship between this phenomenon and the development of VD. The most likely explanation is that sclerotherapy liberates biological mediators, or other factors, from treated venous endothelium and these reach the brain resulting in cortical spreading depression in susceptible patients. This is the underlying mechanism of migraine with aura which is considered to be the most likely cause of the VD. No long-term neurological deficit has been found to arise from this phenomenon. Further research is needed to explore the mechanism of VD, event reporting and documentation should be thoroughly performed to enable exact analysis of such events.</p>
</sec>
</body>
<back>
<ref-list><title>References</title>
<ref id="bibr1-phleb.2012.012051"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Linde</surname><given-names>N</given-names></name><name><surname>Duff</surname><given-names>C</given-names></name><name><surname>Jeanneret</surname><given-names>C</given-names></name><name><surname>Chandler</surname><given-names>JG</given-names></name><name><surname>Seeber</surname><given-names>P</given-names></name></person-group>. <article-title>Late recurrent saphenofemoral junction reflux after ligation and stripping of the greater saphenous vein</article-title>. <source>J Vasc Surg</source> <year>2001</year>;<volume>34</volume>:<fpage>236</fpage>–<lpage>40</lpage></citation></ref>
<ref id="bibr2-phleb.2012.012051"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merchant</surname><given-names>RF</given-names></name><name><surname>Pichot</surname><given-names>O</given-names></name></person-group>. <article-title>Long-term outcomes of endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial venous insufficiency</article-title>. <source>J Vasc Surg</source> <year>2005</year>;<volume>42</volume>:<fpage>502</fpage>–<lpage>9</lpage>; <comment>discussion 509</comment></citation></ref>
<ref id="bibr3-phleb.2012.012051"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mundy</surname><given-names>L</given-names></name><name><surname>Merlin</surname><given-names>TL</given-names></name><name><surname>Fitridge</surname><given-names>RA</given-names></name><name><surname>Hiller</surname><given-names>JE</given-names></name></person-group>. <article-title>Systematic review of endovenous laser treatment for varicose veins</article-title>. <source>Br J Surg</source> <year>2005</year>;<volume>92</volume>:<fpage>1189</fpage>–<lpage>94</lpage></citation></ref>
<ref id="bibr4-phleb.2012.012051"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cabrera</surname><given-names>J</given-names></name><name><surname>Cabrera</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Garcia-Olmedo</surname><given-names>MA</given-names></name></person-group>. <article-title>Sclerosants in microfoam. A new approach in angiology</article-title>. <source>Int Angiol</source> <year>2001</year>;<volume>20</volume>:<fpage>322</fpage>–<lpage>9</lpage></citation></ref>
<ref id="bibr5-phleb.2012.012051"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schadeck</surname><given-names>M</given-names></name><name><surname>Allaert</surname><given-names>F</given-names></name></person-group>. <article-title>[Ultrasonography during sclerotherapy]</article-title>. <source>Phlebologie</source> <year>1991</year>;<volume>44</volume>:<fpage>111</fpage>–<lpage>29</lpage>; <comment>discussion 130</comment></citation></ref>
<ref id="bibr6-phleb.2012.012051"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darvall</surname><given-names>KA</given-names></name><name><surname>Bate</surname><given-names>GR</given-names></name><name><surname>Adam</surname><given-names>DJ</given-names></name><name><surname>Silverman</surname><given-names>SH</given-names></name><name><surname>Bradbury</surname><given-names>AW</given-names></name></person-group>. <article-title>Duplex ultrasound outcomes following ultrasound-guided foam sclerotherapy of symptomatic primary great saphenous varicose veins</article-title>. <source>Eur J Vasc Endovasc Surg</source> <year>2010</year>;<volume>40</volume>:<fpage>534</fpage>–<lpage>9</lpage></citation></ref>
<ref id="bibr7-phleb.2012.012051"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coleridge Smith</surname><given-names>P</given-names></name></person-group>. <article-title>Sclerotherapy and foam sclerotherapy for varicose veins</article-title>. <source>Phlebology</source> <year>2009</year>;<volume>24</volume>:<fpage>260</fpage>–<lpage>9</lpage></citation></ref>
<ref id="bibr8-phleb.2012.012051"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarvananthan</surname><given-names>T</given-names></name><name><surname>Shepherd</surname><given-names>AC</given-names></name><name><surname>Willenberg</surname><given-names>T</given-names></name><name><surname>Davies</surname><given-names>AH</given-names></name></person-group>. <article-title>Neurological complications of sclerotherapy for varicose veins</article-title>. <source>J Vasc Surg</source> <year>2011</year>;<volume>55</volume>:<fpage>243</fpage>–<lpage>51</lpage></citation></ref>
<ref id="bibr9-phleb.2012.012051"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caggiati</surname><given-names>A</given-names></name><name><surname>Franceschini</surname><given-names>M</given-names></name></person-group>. <article-title>Stroke following endovenous laser treatment of varicose veins</article-title>. <source>J Vasc Surg</source> <year>2010</year>;<volume>51</volume>:<fpage>218</fpage>–<lpage>20</lpage></citation></ref>
<ref id="bibr10-phleb.2012.012051"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harzheim</surname><given-names>M</given-names></name><name><surname>Becher</surname><given-names>H</given-names></name><name><surname>Klockgether</surname><given-names>T</given-names></name></person-group>. <article-title>[Brain infarct from a paradoxical embolism following a varices operation]</article-title>. <source>Dtsch Med Wochenschr</source> <year>2000</year>;<volume>125</volume>:<fpage>794</fpage>–<lpage>6</lpage></citation></ref>
<ref id="bibr11-phleb.2012.012051"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frullini</surname><given-names>A</given-names></name><name><surname>Felice</surname><given-names>F</given-names></name><name><surname>Burchielli</surname><given-names>S</given-names></name><name><surname>Di Stefano</surname><given-names>R</given-names></name></person-group>. <article-title>High production of endothelin after foam sclerotherapy: a new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy</article-title>. <source>Phlebology</source> <year>2011</year>;<volume>26</volume>:<fpage>203</fpage>–<lpage>8</lpage></citation></ref>
<ref id="bibr12-phleb.2012.012051"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergan</surname><given-names>J</given-names></name><name><surname>Pascarella</surname><given-names>L</given-names></name><name><surname>Mekenas</surname><given-names>L</given-names></name></person-group>. <article-title>Venous disorders: treatment with sclerosant foam</article-title>. <source>J Cardiovasc Surg (Torino)</source> <year>2006</year>;<volume>47</volume>:<fpage>9</fpage>–<lpage>18</lpage></citation></ref>
<ref id="bibr13-phleb.2012.012051"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhogal</surname><given-names>R</given-names></name><name><surname>Moffat</surname><given-names>CE</given-names></name></person-group>. <article-title>Foam sclerotherapy for bilateral varicose veins: bilateral vs interval unilateral procedures: Published abstract from the Venous Forum 3–4 April 2008</article-title>. <source>Phlebology</source> <year>2008</year>;<volume>23</volume>:<fpage>201</fpage></citation></ref>
<ref id="bibr14-phleb.2012.012051"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cabrera</surname><given-names>J</given-names></name><name><surname>Redondo</surname><given-names>P</given-names></name><name><surname>Becerra</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Ultrasound-guided injection of polidocanol microfoam in the management of venous leg ulcers</article-title>. <source>Arch Dermatol</source> <year>2004</year>;<volume>140</volume>:<fpage>667</fpage>–<lpage>73</lpage></citation></ref>
<ref id="bibr15-phleb.2012.012051"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavezzi</surname><given-names>A</given-names></name><name><surname>Frullini</surname><given-names>A</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Tessari</surname><given-names>A</given-names></name></person-group>. <article-title>Treatment of varicose veins by foam Sclerotherapy: two clinical series</article-title>. <source>Phlebology</source> <year>2002</year>;<volume>17</volume>:<fpage>13</fpage>–<lpage>8</lpage></citation></ref>
<ref id="bibr16-phleb.2012.012051"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ceulen</surname><given-names>RP</given-names></name><name><surname>Sommer</surname><given-names>A</given-names></name><name><surname>Vernooy</surname><given-names>K</given-names></name></person-group>. <article-title>Microembolism during foam sclerotherapy of varicose veins</article-title>. <source>N Engl J Med</source> <year>2008</year>;<volume>358</volume>:<fpage>1525</fpage>–<lpage>6</lpage></citation></ref>
<ref id="bibr17-phleb.2012.012051"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darke</surname><given-names>SG</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name></person-group>. <article-title>Ultrasound-guided foam sclerotherapy for the treatment of varicose veins</article-title>. <source>Br J Surg</source> <year>2006</year>;<volume>93</volume>:<fpage>969</fpage>–<lpage>74</lpage></citation></ref>
<ref id="bibr18-phleb.2012.012051"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frullini</surname><given-names>A</given-names></name></person-group>. <article-title>New technique in producing sclerosing foam in a disposable syringe</article-title>. <source>Dermatol Surg</source> <year>2000</year>;<volume>26</volume>:<fpage>705</fpage>–<lpage>6</lpage></citation></ref>
<ref id="bibr19-phleb.2012.012051"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frullini</surname><given-names>A</given-names></name><name><surname>Cavezzi</surname><given-names>A</given-names></name></person-group>. <article-title>Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications</article-title>. <source>Dermatol Surg</source> <year>2002</year>;<volume>28</volume>:<fpage>11</fpage>–<lpage>5</lpage></citation></ref>
<ref id="bibr20-phleb.2012.012051"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gillet</surname><given-names>JL</given-names></name><name><surname>Guedes</surname><given-names>JM</given-names></name><name><surname>Guex</surname><given-names>JJ</given-names></name><etal/></person-group> <article-title>Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1025 patients</article-title>. <source>Phlebology</source> <year>2009</year>;<volume>24</volume>:<fpage>131</fpage>–<lpage>8</lpage></citation></ref>
<ref id="bibr21-phleb.2012.012051"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>P</given-names></name><name><surname>Ramelet</surname><given-names>AA</given-names></name><name><surname>Wutschert</surname><given-names>R</given-names></name><name><surname>Bounameaux</surname><given-names>H</given-names></name><name><surname>Hayoz</surname><given-names>D</given-names></name></person-group>. <article-title>Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins</article-title>. <source>Dermatol Surg</source> <year>2004</year>;<volume>30</volume>:<fpage>367</fpage>–<lpage>72</lpage>; <comment>discussion 372</comment></citation></ref>
<ref id="bibr22-phleb.2012.012051"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>N</given-names></name><name><surname>Neuhardt</surname><given-names>DL</given-names></name><name><surname>Rogers</surname><given-names>CR</given-names></name><etal/></person-group> <article-title>Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation</article-title>. <source>J Vasc Surg</source> <year>2008</year>;<volume>47</volume>:<fpage>830</fpage>–<lpage>6</lpage></citation></ref>
<ref id="bibr23-phleb.2012.012051"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>KA</given-names></name><name><surname>Jolley</surname><given-names>D</given-names></name><name><surname>Clough</surname><given-names>A</given-names></name><name><surname>Kirwan</surname><given-names>J</given-names></name></person-group>. <article-title>Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance</article-title>. <source>Eur J Vasc Endovasc Surg</source> <year>2007</year>;<volume>33</volume>:<fpage>116</fpage>–<lpage>21</lpage></citation></ref>
<ref id="bibr24-phleb.2012.012051"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Yun</surname><given-names>IJ</given-names></name><name><surname>Hwang</surname><given-names>JJ</given-names></name><etal/></person-group> <article-title>Fluoroscopy-guided endovenous foam sclerotherapy using a microcatheter in varicose tributaries followed by endovenous laser treatment of incompetent saphenous veins: technical feasibility and early results</article-title>. <source>Dermatol Surg</source> <year>2009</year>;<volume>35</volume>:<fpage>804</fpage>–<lpage>12</lpage></citation></ref>
<ref id="bibr25-phleb.2012.012051"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raymond-Martimbeau</surname><given-names>P</given-names></name></person-group>. <article-title>Transient adverse events positively associated with patent foramen ovale after ultrasound-guided foam sclerotherapy</article-title>. <source>Phlebology</source> <year>2009</year>;<volume>24</volume>:<fpage>114</fpage>–<lpage>9</lpage></citation></ref>
<ref id="bibr26-phleb.2012.012051"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PC</given-names></name></person-group>. <article-title>Chronic venous disease treated by ultrasound guided foam sclerotherapy</article-title>. <source>Eur J Vasc Endovasc Surg</source> <year>2006</year>;<volume>32</volume>:<fpage>577</fpage>–<lpage>83</lpage></citation></ref>
<ref id="bibr27-phleb.2012.012051"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tessari</surname><given-names>L</given-names></name><name><surname>Cavezzi</surname><given-names>A</given-names></name><name><surname>Frullini</surname><given-names>A</given-names></name></person-group>. <article-title>Preliminary experience with a new sclerosing foam in the treatment of varicose veins</article-title>. <source>Dermatol Surg</source> <year>2001</year>;<volume>27</volume>:<fpage>58</fpage>–<lpage>60</lpage></citation></ref>
<ref id="bibr28-phleb.2012.012051"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>D</given-names></name><name><surname>Gobin</surname><given-names>JP</given-names></name><name><surname>Bradbury</surname><given-names>AW</given-names></name><etal/></person-group> <article-title>Varisolve R polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial</article-title>. <source>Phlebology</source> <year>2006</year>;<volume>21</volume>:<fpage>180</fpage>–<lpage>90</lpage></citation></ref>
<ref id="bibr29-phleb.2012.012051"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>K</given-names></name><name><surname>Harms</surname><given-names>L</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name></person-group>. <article-title>Reversible neurological deficit after foam sclerotherapy</article-title>. <source>Eur J Vasc Endovasc Surg</source> <year>2009</year>;<volume>38</volume>:<fpage>648</fpage>–<lpage>9</lpage></citation></ref>
<ref id="bibr30-phleb.2012.012051"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradbury</surname><given-names>AW</given-names></name><name><surname>Bate</surname><given-names>G</given-names></name><name><surname>Pang</surname><given-names>K</given-names></name><name><surname>Darvall</surname><given-names>KA</given-names></name><name><surname>Adam</surname><given-names>DJ</given-names></name></person-group>. <article-title>Ultrasound-guided foam sclerotherapy is a safe and clinically effective treatment for superficial venous reflux</article-title>. <source>J Vasc Surg</source> <year>2010</year>;<volume>52</volume>:<fpage>939</fpage>–<lpage>45</lpage></citation></ref>
<ref id="bibr31-phleb.2012.012051"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henriet</surname><given-names>JP</given-names></name></person-group>. <article-title>Expérience durant trois années de la mousse de polidocanol dans le traitement des varices réticulaires et des varicosités</article-title>. <source>Phléblogie</source> <year>1999</year>;<volume>52</volume>:<fpage>277</fpage>–<lpage>82</lpage></citation></ref>
<ref id="bibr32-phleb.2012.012051"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alos</surname><given-names>J</given-names></name><name><surname>Carreno</surname><given-names>P</given-names></name><name><surname>Lopez</surname><given-names>JA</given-names></name><name><surname>Estadella</surname><given-names>B</given-names></name><name><surname>Serra-Prat</surname><given-names>M</given-names></name><name><surname>Marinel-Lo</surname><given-names>J</given-names></name></person-group>. <article-title>Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial</article-title>. <source>Eur J Vasc Endovasc Surg</source> <year>2006</year>;<volume>31</volume>:<fpage>101</fpage>–<lpage>7</lpage></citation></ref>
<ref id="bibr33-phleb.2012.012051"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouvry</surname><given-names>P</given-names></name><name><surname>Allaert</surname><given-names>FA</given-names></name><name><surname>Desnos</surname><given-names>P</given-names></name><name><surname>Hamel-Desnos</surname><given-names>C</given-names></name></person-group>. <article-title>Efficacy of polidocanol foam vs liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up</article-title>. <source>Eur J Vasc Endovasc Surg</source> <year>2008</year>;<volume>36</volume>:<fpage>366</fpage>–<lpage>70</lpage></citation></ref>
<ref id="bibr34-phleb.2012.012051"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gillet</surname><given-names>JL</given-names></name><name><surname>Donnet</surname><given-names>A</given-names></name><name><surname>Lausecker</surname><given-names>M</given-names></name><name><surname>Guedes</surname><given-names>JM</given-names></name><name><surname>Guex</surname><given-names>JJ</given-names></name><name><surname>Lehmann</surname><given-names>P</given-names></name></person-group>. <article-title>Pathophysiology of visual disturbances occurring after foam sclerotherapy</article-title>. <source>Phlebology</source> <year>2010</year>;<volume>25</volume>:<fpage>261</fpage>–<lpage>6</lpage></citation></ref>
<ref id="bibr35-phleb.2012.012051"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>E</given-names></name><name><surname>Schliephake</surname><given-names>D</given-names></name><name><surname>Otto</surname><given-names>J</given-names></name><name><surname>Breu</surname><given-names>FX</given-names></name><name><surname>Pannier</surname><given-names>F</given-names></name></person-group>. <article-title>Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study)</article-title>. <source>Phlebology</source> <year>2010</year>;<volume>25</volume>:<fpage>124</fpage>–<lpage>31</lpage></citation></ref>
<ref id="bibr36-phleb.2012.012051"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>E</given-names></name><name><surname>Otto</surname><given-names>J</given-names></name><name><surname>Schliephake</surname><given-names>D</given-names></name><name><surname>Pannier</surname><given-names>F</given-names></name></person-group>. <article-title>Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial</article-title>. <source>Eur J Vasc Endovasc Surg</source> <year>2008</year>;<volume>35</volume>:<fpage>238</fpage>–<lpage>45</lpage></citation></ref>
<ref id="bibr37-phleb.2012.012051"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahle</surname><given-names>B</given-names></name><name><surname>Leng</surname><given-names>K</given-names></name></person-group>. <article-title>Efficacy of sclerotherapy in varicose veins – prospective, blinded, placebo-controlled study</article-title>. <source>Dermatol Surg</source> <year>2004</year>;<volume>30</volume>:<fpage>723</fpage>–<lpage>8</lpage>; <comment>discussion 728</comment></citation></ref>
<ref id="bibr38-phleb.2012.012051"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamel-Desnos</surname><given-names>C</given-names></name><name><surname>Desnos</surname><given-names>P</given-names></name><name><surname>Wollmann</surname><given-names>JC</given-names></name><name><surname>Ouvry</surname><given-names>P</given-names></name><name><surname>Mako</surname><given-names>S</given-names></name><name><surname>Allaert</surname><given-names>FA</given-names></name></person-group>. <article-title>Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results</article-title>. <source>Dermatol Surg</source> <year>2003</year>;<volume>29</volume>:<fpage>1170</fpage>–<lpage>5</lpage>; <comment>discussion 1175</comment></citation></ref>
<ref id="bibr39-phleb.2012.012051"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamaki</surname><given-names>T</given-names></name><name><surname>Nozaki</surname><given-names>M</given-names></name><name><surname>Iwasaka</surname><given-names>S</given-names></name></person-group>. <article-title>Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency</article-title>. <source>Dermatol Surg</source> <year>2004</year>;<volume>30</volume>:<fpage>718</fpage>–<lpage>22</lpage>; <comment>discussion 722</comment></citation></ref>
<ref id="bibr40-phleb.2012.012051"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>J</given-names></name><name><surname>Wildemore</surname><given-names>JK</given-names></name><name><surname>Goldman</surname><given-names>MP</given-names></name></person-group>. <article-title>Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins</article-title>. <source>Dermatol Surg</source> <year>2005</year>;<volume>31</volume>:<fpage>631</fpage>–<lpage>5</lpage>; <comment>discussion 635</comment></citation></ref>
<ref id="bibr41-phleb.2012.012051"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kakkos</surname><given-names>SK</given-names></name><name><surname>Bountouroglou</surname><given-names>DG</given-names></name><name><surname>Azzam</surname><given-names>M</given-names></name><name><surname>Kalodiki</surname><given-names>E</given-names></name><name><surname>Daskalopoulos</surname><given-names>M</given-names></name><name><surname>Geroulakos</surname><given-names>G</given-names></name></person-group>. <article-title>Effectiveness and safety of ultrasound-guided foam sclerotherapy for recurrent varicose veins: immediate results</article-title>. <source>J Endovasc Ther</source> <year>2006</year>;<volume>13</volume>:<fpage>357</fpage>–<lpage>64</lpage></citation></ref>
<ref id="bibr42-phleb.2012.012051"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guex</surname><given-names>JJ</given-names></name><name><surname>Allaert</surname><given-names>FA</given-names></name><name><surname>Gillet</surname><given-names>JL</given-names></name><name><surname>Chleir</surname><given-names>F</given-names></name></person-group>. <article-title>Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions</article-title>. <source>Dermatol Surg</source> <year>2005</year>;<volume>31</volume>:<fpage>123</fpage>–<lpage>8</lpage>; <comment>discussion 128</comment></citation></ref>
<ref id="bibr43-phleb.2012.012051"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunzlberger</surname><given-names>B</given-names></name><name><surname>Pieck</surname><given-names>C</given-names></name><name><surname>Altmeyer</surname><given-names>P</given-names></name><name><surname>Stucker</surname><given-names>M</given-names></name></person-group>. <article-title>Migraine ophthalmique with reversible scotomas after sclerotherapy with liquid 1% polidocanol</article-title>. <source>Dermatol Surg</source> <year>2006</year>;<volume>32</volume>:<fpage>1410</fpage>–<lpage>3</lpage></citation></ref>
<ref id="bibr44-phleb.2012.012051"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wallois</surname><given-names>P</given-names></name></person-group>. <article-title>[Incidents and accidents in the sclerosing treatment of varicose veins and their prevention]</article-title>. <source>Phlebologie</source> <year>1971</year>;<volume>24</volume>:<fpage>217</fpage>–<lpage>24</lpage></citation></ref>
<ref id="bibr45-phleb.2012.012051"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexakis</surname><given-names>C</given-names></name><name><surname>Caruelle</surname><given-names>JP</given-names></name><name><surname>Sezeur</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents</article-title>. <source>Gut</source> <year>2004</year>;<volume>53</volume>:<fpage>85</fpage>–<lpage>90</lpage></citation></ref>
<ref id="bibr46-phleb.2012.012051"><label>46</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Golman</surname><given-names>M</given-names></name><name><surname>Bergan</surname><given-names>J</given-names></name></person-group>. <source>Complications and Adverse Sequelae of Sclerotherapy</source>. <edition>3rd edn</edition>. <publisher-loc>St Louis MO, USA</publisher-loc>: <publisher-name>Mosby</publisher-name>, <year>2001</year>:<fpage>231</fpage></citation></ref>
<ref id="bibr47-phleb.2012.012051"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McAusland</surname><given-names>S</given-names></name></person-group>. <article-title>The modern treatment of varicose veins</article-title>. <source>Med Press Circular</source> <year>1939</year>;<volume>201</volume>:<fpage>404</fpage>–<lpage>10</lpage></citation></ref>
<ref id="bibr48-phleb.2012.012051"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orbach</surname><given-names>EJ</given-names></name></person-group>. <article-title>Sclerotherapy of varicose veins. Utilization of an intravenous air block</article-title>. <source>Am J Surg</source> <year>1944</year>;<volume>LXVI</volume>:<fpage>362</fpage>–<lpage>6</lpage></citation></ref>
<ref id="bibr49-phleb.2012.012051"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cabrera</surname><given-names>C</given-names></name><name><surname>Garcia-Olmedo</surname><given-names>C</given-names></name></person-group>. <article-title>Nuevo método de esclerosis en las varices tronculares</article-title>. <source>Patol Vasc</source> <year>1995</year>;<volume>4</volume>:<fpage>35</fpage>–<lpage>7</lpage></citation></ref>
<ref id="bibr50-phleb.2012.012051"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Charbit</surname><given-names>AR</given-names></name><name><surname>Andreou</surname><given-names>AP</given-names></name><name><surname>Akerman</surname><given-names>S</given-names></name><name><surname>Holland</surname><given-names>PR</given-names></name></person-group>. <article-title>Neurobiology of migraine</article-title>. <source>Neuroscience</source> <year>2009</year>;<volume>161</volume>:<fpage>327</fpage>–<lpage>41</lpage></citation></ref>
<ref id="bibr51-phleb.2012.012051"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orsini</surname><given-names>C</given-names></name><name><surname>Brotto</surname><given-names>M</given-names></name></person-group>. <article-title>Immediate pathologic effects on the vein wall of foam sclerotherapy</article-title>. <source>Dermatol Surg</source> <year>2007</year>;<volume>33</volume>:<fpage>1250</fpage>–<lpage>4</lpage></citation></ref>
<ref id="bibr52-phleb.2012.012051"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guex</surname><given-names>JJ</given-names></name></person-group>. <article-title>Complications and side-effects of foam sclerotherapy</article-title>. <source>Phlebology</source> <year>2009</year>;<volume>24</volume>:<fpage>270</fpage>–<lpage>4</lpage></citation></ref>
<ref id="bibr53-phleb.2012.012051"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dreier</surname><given-names>JP</given-names></name><name><surname>Kleeberg</surname><given-names>J</given-names></name><name><surname>Alam</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Endothelin-1-induced spreading depression in rats is associated with a microarea of selective neuronal necrosis</article-title>. <source>Exp Biol Med (Maywood)</source> <year>2007</year>;<volume>232</volume>:<fpage>204</fpage>–<lpage>13</lpage></citation></ref>
<ref id="bibr54-phleb.2012.012051"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsi</surname><given-names>K</given-names></name><name><surname>Connor</surname><given-names>DE</given-names></name><name><surname>Pilotelle</surname><given-names>A</given-names></name><name><surname>Low</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>DD</given-names></name><name><surname>Joseph</surname><given-names>JE</given-names></name></person-group>. <article-title>Low concentration detergent sclerosants induce platelet activation but inhibit aggregation due to suppression of GPIIb/IIIa activation <italic>in vitro</italic></article-title>. <source>Thromb Res</source> <year>2012</year>;<volume>130</volume>(<issue>3</issue>):<fpage>472</fpage>–<lpage>8</lpage></citation></ref>
<ref id="bibr55-phleb.2012.012051"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Sacco</surname><given-names>RL</given-names></name></person-group>. <article-title>Patent foramen ovale and stroke</article-title>. <source>Circulation</source> <year>2005</year>;<volume>112</volume>:<fpage>1063</fpage>–<lpage>72</lpage></citation></ref>
<ref id="bibr56-phleb.2012.012051"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>DD</given-names></name><name><surname>Gibson</surname><given-names>KD</given-names></name><name><surname>Barclay</surname><given-names>J</given-names></name><name><surname>Razumovsky</surname><given-names>A</given-names></name><name><surname>Rush</surname><given-names>J</given-names></name><name><surname>McCollum</surname><given-names>CN</given-names></name></person-group>. <article-title>High prevalence of right-to-left shunt in patients with symptomatic great saphenous incompetence and varicose veins</article-title>. <source>J Vasc Surg</source> <year>2009</year>;<volume>51</volume>:<fpage>104</fpage>–<lpage>7</lpage></citation></ref>
<ref id="bibr57-phleb.2012.012051"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Regan</surname><given-names>JD</given-names></name><name><surname>Gibson</surname><given-names>KD</given-names></name><name><surname>Rush</surname><given-names>JE</given-names></name><name><surname>Shortell</surname><given-names>CK</given-names></name><name><surname>Hirsch</surname><given-names>SA</given-names></name><name><surname>Wright</surname><given-names>DD</given-names></name></person-group>. <article-title>Clinical significance of cerebrovascular gas emboli during polidocanol endovenous ultra-low nitrogen microfoam ablation and correlation with magnetic resonance imaging in patients with right-to-left shunt</article-title>. <source>J Vasc Surg</source> <year>2011</year>;<volume>53</volume>:<fpage>131</fpage>–<lpage>7</lpage></citation></ref>
<ref id="bibr58-phleb.2012.012051"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>K</given-names></name><name><surname>Morrison</surname><given-names>N</given-names></name><name><surname>Neuhardt</surname><given-names>D</given-names></name><name><surname>Salles-Cunha</surname><given-names>S</given-names></name></person-group>. <article-title>Transthoracic echocardiogram and transcranial Doppler detection of emboli after foam sclerotherapy of leg veins</article-title>. <source>J Vasc Ultrasound</source> <year>2007</year>;<volume>31</volume>:<fpage>213</fpage>–<lpage>6</lpage></citation></ref>
<ref id="bibr59-phleb.2012.012051"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Breu</surname><given-names>FX</given-names></name><name><surname>Guggenbichler</surname><given-names>S</given-names></name><name><surname>Wollmann</surname><given-names>JC</given-names></name></person-group>. <article-title>2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany</article-title>. <source>Vasa</source> <year>2008</year>;<volume>37</volume>(<supplement>Suppl. 71</supplement>):<fpage>1</fpage>–<lpage>29</lpage></citation></ref>
<ref id="bibr60-phleb.2012.012051"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hesse</surname><given-names>G</given-names></name><name><surname>Breu</surname><given-names>FX</given-names></name><name><surname>Kuschmann</surname><given-names>K</given-names></name><name><surname>Hartmann</surname><given-names>K</given-names></name><name><surname>Salomon</surname><given-names>M</given-names></name></person-group>. <article-title>Sclerotherapy using air – or CO<sub>2</sub>-O<sub>2</sub> foam</article-title>. <source>Phlebologie</source> <year>2012</year>;<volume>41</volume>:<fpage>77</fpage>–<lpage>88</lpage></citation></ref>
<ref id="bibr61-phleb.2012.012051"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsi</surname><given-names>K</given-names></name></person-group>. <article-title>Venous gas embolism during foam sclerotherapy of saphenous veins despite recommended treatment modifications</article-title>. <source>Phlebology</source> <year>2011</year>;<volume>26</volume>:<fpage>140</fpage>–<lpage>7</lpage></citation></ref></ref-list>
</back>
</article>